OTCMKTS:PHGUF Pharming Group (PHGUF) Stock Price, News & Analysis $1.28 +0.04 (+3.23%) As of 03:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Pharming Group Stock (OTCMKTS:PHGUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$1.28▼$1.2850-Day Range$1.24▼$1.7552-Week Range$1.11▼$2.17Volume230 shsAverage Volume7,133 shsMarket Capitalization$858.97 millionP/E Ratio64.03Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies. Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders. Lead pipeline candidates include odiparcil for mucopolysaccharidosis type VI and investigational therapies aimed at chronic inflammatory and complement-mediated conditions. The company conducts clinical trials across multiple regions and collaborates with partners such as Chiesi and other specialty pharma organizations to advance its programs through regulatory review, manufacturing scale-up and commercial launch preparations. Pharming Group’s operations span North America, Europe and select markets in Asia and Latin America, reflecting its global commercialization footprint. The company’s leadership team is headed by CEO Roy van den Berg, supported by a management team with extensive experience in biotechnology R&D, global regulatory affairs and specialty-product marketing. Pharming Group is listed on Euronext Amsterdam (symbol PHARM) and trades in the United States on the OTC market under the symbol PHGUF.AI Generated. May Contain Errors. Read More Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHGUF Stock News HeadlinesPharming Group Balances Near-Term Strain With Joenja GrowthMay 20 at 1:30 AM | tipranks.comPharming Group Balances Short-Term Strain With Pipeline GainsMay 7, 2026 | tipranks.comNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 20 at 1:00 AM | Porter & Company (Ad)Pharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026May 7, 2026 | tipranks.comPharming Group to report first quarter 2026 financial results and provide business update on May 7April 23, 2026 | uk.finance.yahoo.comPharming Group N.V.: Pharming Group announces the 2026 Annual General Meeting of ShareholdersApril 16, 2026 | finanznachrichten.dePharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on AgendaApril 16, 2026 | tipranks.comCanaccord Genuity initiates coverage of Pharming Group NV - Depositary Receipt (PHAR) with buy recommendationApril 11, 2026 | msn.comSee More Headlines PHGUF Stock Analysis - Frequently Asked Questions How have PHGUF shares performed this year? Pharming Group's stock was trading at $1.65 at the start of the year. Since then, PHGUF shares have decreased by 22.4% and is now trading at $1.28. How were Pharming Group's earnings last quarter? Pharming Group NV (OTCMKTS:PHGUF) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.00 by $0.01. The biotechnology company had revenue of $72.45 million for the quarter, compared to analysts' expectations of $92.06 million. Pharming Group had a trailing twelve-month return on equity of 4.68% and a net margin of 3.30%. How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today5/20/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees382Year Founded1988Profitability EPS (Trailing Twelve Months)$0.02 Trailing P/E Ratio64.03 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.85 million Net Margins3.30% Pretax Margin3.42% Return on Equity4.68% Return on Assets2.57% Debt Debt-to-Equity Ratio0.39 Current Ratio2.59 Quick Ratio2.03 Sales & Book Value Annual Sales$376.13 million Price / Sales2.28 Cash Flow$0.02 per share Price / Cash Flow59.15 Book Value$0.41 per share Price / Book3.12Miscellaneous Outstanding Shares671,070,000Free FloatN/AMarket Cap$858.97 million OptionableNot Optionable Beta0.55 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:PHGUF) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredWhat Netscape taught us about the next big infrastructure playSpaceX doesn't function without autonomous flight systems, AI navigation, semiconductor chips, and real-time d...True Market Insiders | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredMissed Nvidia’s 44,000%? This is the next big opportunityIn February 2016, Louis Navellier recommended Nvidia at $2.51 split-adjusted - before a 44,000% gain. He also ...InvestorPlace | SponsoredForget SpaceX. Buy the company Musk can't replace.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
